Indivior Reports Record Q3 Net Income of $137 Million and Adjusted EBITDA of $211 Million
Indivior reported Q3 2026 revenue of $356M, up 13% YoY, with record net income of $137M and adjusted EBITDA of $211M. SUBLOCADE prescriptions surpassed 583,000 U.S. patients. The company's merger with Supernus is expected to close November 2, with the combined entity trading as SUPN.
How this was made
The 30-second read
Why it matters
The earnings beat and merger announcement provide fresh, material information that can move the stock.
Market read
Record earnings and a definitive merger timeline create a clear short‑term trading catalyst for INDV.
What to watch
Potential integration costs and dilution from the all‑stock deal are not detailed.
Background
Indivior Pharmaceuticals released its Q3 2026 earnings and disclosed an all‑stock merger with Supernus, slated to close on Nov 2.
Ticker impact
Indivior reported Q3 2026 revenue of $356M, net income $137M and announced its all‑stock merger with Supernus expected to close Nov 2.
likely upward pressure as investors price in record earnings and merger completion
Record net income and a clear merger timeline provide concrete catalysts for short‑term buying.
Market effects
Pharma sector may see modest rally as a peer reports strong earnings and consolidation.
U.S. healthcare stocks could benefit from the merger news.
Limited to investors focused on U.S. specialty pharma and M&A activity.
Counterpoint
If the merger faces regulatory hurdles, the stock could face downside pressure.
Key entities
- companyIndivior Pharmaceuticals
U.S. specialty pharma company reporting earnings and merger.
- companySupernus
Merger partner; combined entity will trade under SUPN.
